These cases provide evidence for a fingolimod rebound syndrome at a clinically relevant frequency, highlighting the need to determine the best methods for sequencing or discontinuing MS therapies. A large prospective registry or population-based study would be helpful to confirm this rebound phenomenon and to determine contributing factors, including immune biomarkers, that increase risk for this syndrome.
No takes yet. Share an insight, caveat, or question.
Hatcher et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: